New targeted pill takes on tough lung cancer in major trial
NCT ID NCT06281964
First seen Dec 29, 2025 · Last updated May 14, 2026 · Updated 19 times
Summary
This study tests a new oral drug, PLB1004, against standard chemotherapy (with or without an immunotherapy) in about 327 people with advanced non-small-cell lung cancer that has a specific genetic change called EGFR exon 20 insertion. The goal is to see if PLB1004 can keep the cancer from growing longer than chemo. Participants must have confirmed EGFR Exon20ins and have not had prior treatment for advanced disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Guangdong Provincial People's Hospital
Guangzhou, Guangzhou, 510080, China
Conditions
Explore the condition pages connected to this study.